Princess Diana captured on CCTV as she left the Ritz Hotel in Paris shortly before her death in a car crash in 1997.[Reuters] The UK government has finally released a heavily redacted official log detailing the events following the death of Princess Diana in 1997.
SAN DIEGO, April 11, 2017 /PRNewswire/-- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZAâ¢ (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).
The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal. An estimated 25.8 million (18.8 million diagnosed and 7.0 million undiagnosed) people in the United States or approximately 8.3 percent of the populationâhave diabetes.